Inhibition of BACE-1 proteolytic activity decreases Aβ generation and amyloid deposition, and thus has been an important focus in AD clinical trials, unfortunately with little therapeutic success [77], (Table 1). This evidence concerns the gene BACE1 and Alzheimer disease.